Imugene (ASX:IMU) has announced 3 patients in its latest blood cancer treatment trial using azer-cel have responded well with one showing a complete response for over 100 days. A ‘complete response’ in this case is a complete disappearance of all tumours. The company is focusing on patients with Diffuse large B-cell lymphoma (DLBCL) who have relapsed after using prior treatments before. Three patients from two cohorts showed particularly strong reactions where tumours disappeared – a total of ten patients were involved. Recruitment remains ongoing to test azer-cel in multiple countries. Two of…